<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H75EB7FC5E5EE47FFBA8CC4399121A012" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 1476 IH: Preserving Life-saving Access to Specialty Medicines in America Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-02-21</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1476</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250221">February 21, 2025</action-date><action-desc><sponsor name-id="H001067">Mr. Hudson</sponsor> (for himself, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, <cosponsor name-id="M001210">Mr. Murphy</cosponsor>, and <cosponsor name-id="P000608">Mr. Peters</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.</official-title></form><legis-body id="H49C2CC5FE7384ECDBA75C61D8A8E55E1" style="OLC"> 
<section id="HCB9FBDBD90CC4703975CBBFAD28E1264" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Preserving Life-saving Access to Specialty Medicines in America Act</short-title></quote> or the <quote><short-title>PLASMA Act</short-title></quote>.</text></section> <section id="H41DFC03277DB49EFB40209E92592C147" section-type="subsequent-section"><enum>2.</enum><header>Phase-in for plasma-derived products under manufacturer discount program</header><text display-inline="no-display-inline">Section 1860D–14C(g)(4) of the Social Security Act (42 U.S.C. 1395w–114c(g)(4)) is amended—</text> 
<paragraph commented="no" display-inline="no-display-inline" id="H394488F8EF1E43C7B5ADFEA1EC4791D4"><enum>(1)</enum><text>in subparagraph (A), in the matter preceding clause (i), by striking <quote>and (C)</quote> and inserting <quote>, (C), and (D)</quote>;</text></paragraph> <paragraph id="H9B87B7C0885A493FAF16470D48951F16"><enum>(2)</enum><text>by redesignating subparagraphs (D) and (E) as subparagraphs (E) and (F), respectively; and</text></paragraph> 
<paragraph id="HEAB2A4240FE84F4382326048931471CE"><enum>(3)</enum><text>by inserting after subparagraph (C) the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="H83C0831CB7BC4E429B3029C56952CBF5"> <subparagraph id="H28AF8D3B3F0E4C4E91020CF91E4DD047"><enum>(D)</enum><header>Phase-in for plasma-derived products</header> <clause id="H89BC991FDF434FCF866CD9C3C1527BC5"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">For 2026 and subsequent years, subject to clause (iv), in the case of an applicable drug of a manufacturer that is a plasma-derived product (as defined in <internal-xref idref="HCE6C17B62D4D4F1DA083BEC53CC514D3" legis-path="(D)(ii)">clause (ii)</internal-xref>), and that is marketed as of August 16, 2022, and dispensed for an applicable beneficiary, the term <term>discounted price</term> means the specified plasma-derived product percent (as defined in <internal-xref idref="H4B4B75845042490D85E13255DEAAA9DE" legis-path="(D)(iii)">clause (iii)</internal-xref>) of the negotiated price of the applicable drug of the manufacturer.</text></clause> 
<clause id="HCE6C17B62D4D4F1DA083BEC53CC514D3"><enum>(ii)</enum><header>Plasma-derived product</header><text>In this subparagraph, the term <term>plasma-derived product</term> means an applicable drug that is a biological product that is derived from human whole blood or plasma.</text></clause> <clause id="H4B4B75845042490D85E13255DEAAA9DE"><enum>(iii)</enum><header>Specified plasma-derived product percent</header><text>In this subparagraph, the term <term>specified plasma-derived product percent</term> means, with respect to a year—</text> 
<subclause id="HFDF6C260FCFA44D081371BD66A116F9C"><enum>(I)</enum><text>for an applicable drug that is a plasma-derived product dispensed for an applicable beneficiary who has not incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year—</text> <item id="H6C4D045399B648D39948BC102A6FD063"><enum>(aa)</enum><text>for 2026, 99 percent;</text></item> 
<item id="H4712E44CBFC4406EA269A4C15DA67745"><enum>(bb)</enum><text display-inline="yes-display-inline">for 2027, 98 percent;</text></item> <item id="H4ABA614431CE45C5A5DD9A2B9F1855EF"><enum>(cc)</enum><text display-inline="yes-display-inline">for 2028, 95 percent;</text></item> 
<item id="H5FD915D3AF55452F9A0E4C128539DF2F"><enum>(dd)</enum><text display-inline="yes-display-inline">for 2029, 92 percent; and</text></item> <item id="H116FCB69CA164A9BBF6ECC1A9F361C3E"><enum>(ee)</enum><text display-inline="yes-display-inline">for 2030 and each subsequent year, 90 percent; and</text></item></subclause> 
<subclause id="H623AEB348BEF4ED19C796D317C47AF76"><enum>(II)</enum><text>for an applicable drug that is a plasma-derived product dispensed for an applicable beneficiary who has incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year—</text> <item id="H9207538F38BA46E98169858DF171D624"><enum>(aa)</enum><text>for 2026, 99 percent;</text></item> 
<item id="H5DA52D48C72345A9B73DB7368B95E951"><enum>(bb)</enum><text display-inline="yes-display-inline">for 2027, 98 percent;</text></item> <item id="HC142E17CE3724123A41110664A5D9E88"><enum>(cc)</enum><text display-inline="yes-display-inline">for 2028, 95 percent;</text></item> 
<item id="HF9E559AB9D6540839FF838937F54474E"><enum>(dd)</enum><text display-inline="yes-display-inline">for 2029, 92 percent;</text></item> <item id="HDD5B7F4E12E449B08F5999749BBC78A0"><enum>(ee)</enum><text display-inline="yes-display-inline">for 2030, 90 percent;</text></item> 
<item id="H8F4FE6FFD98B4EB79B2409C34E6C6D51"><enum>(ff)</enum><text display-inline="yes-display-inline">for 2031, 85 percent; and</text></item> <item id="H1D399BF4994542D0B5744F4B659A2F7C"><enum>(gg)</enum><text display-inline="yes-display-inline">for 2032 and each subsequent year, 80 percent.</text></item></subclause></clause> 
<clause id="H542BD8A939F44D23B3A7D32B7A992012"><enum>(iv)</enum><header>Limitations</header><text>This subparagraph shall not apply with respect to the following:</text> <subclause id="H53A00B8AFD914F1B87464447690DBB26"><enum>(I)</enum><header>Certain drugs dispensed to LIS beneficiaries</header><text>An applicable drug described in subparagraph (B)(i).</text></subclause> 
<subclause id="H9A5505AD24884622A0442E858A16D859"><enum>(II)</enum><header>Specified small manufacturers</header><text>An applicable drug described in subparagraph (C)(i).</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> </legis-body></bill>

